Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-44

It is a progress update which should have been acknowledged by the market as this isn't a given, there are many comps which won't even get that far.

But at the same time it shows that despite Warp - speed in medical terms it is a long waiting game with uncertainties and that's reflected in the dump.

Market wants to see $$$$ in cash or at least as a deal to see the bigger forces acknowledging the progress before they commit, and RAD is evidence for that, but as long as IMU isn't delivering on that front we have to get used to the sp down here or even lower. Forwards looking valuations won't apply anymore, IMU has to do it the old fashioned way of delivering income first and then increasing its valuation, the way the stock markets were founded on.

No rush to buy as results aren't around the corner and anns out of the woodwork aren't that common for IMU. My sp prediction is most likely going lower before reversing higher by end'24 / early '25 if there aren't any delays and / or Cap Raising.

A lot of patience needed,

GLTA